The National Institute for Health and Care Excellence is most visible in the UK as the body that decides which cancer drugs the NHS will pay for. Its Technology Appraisal (TA) work is where the headline debates happen. Quieter, and until recently more niche, is its Highly Specialised Technologies (HST) programme — the pathway through which most of the UK's ultra-expensive gene and cell therapies reach NHS patients.

With a growing number of advanced therapy medicinal products (ATMPs) entering UK clinical use each year, the HST pathway has moved from a footnote of NICE's output to a significant gateway. This piece explains what HST is, what it has approved, and how the decisions shape what community pharmacists see on the counter and what hospital pharmacists manage inside their trusts.

What is Highly Specialised Technologies

The HST programme is NICE's evaluation route for medicines that treat very rare conditions, typically affecting fewer than one in 50,000 people in England. The criteria for eligibility are deliberately narrow — NICE publishes a formal methodology — and only a small number of medicines are routed through HST each year. The HST pathway differs from the standard Technology Appraisal route in three important ways:

• Cost threshold. The HST methodology allows a higher incremental cost-effectiveness ratio (ICER) than standard TA, in recognition of the small patient population over which fixed R&D costs must be spread.
• Weighting for quality-adjusted life years (QALYs). HST uses a QALY weighting that gives extra value to treatments for very severe conditions with long-term benefit.
• Managed access as standard. HST approvals are frequently accompanied by a Managed Access Agreement (see our companion piece on managed access), funding the treatment while additional real-world data is collected.

What has been approved through HST

The list has grown quickly. Examples include:

This is not a complete list; NICE's HST register should be consulted for the current set.

What the table shows is the pattern. HST is where most of the UK's gene therapies, enzyme-replacement therapies for ultra-rare metabolic disease, and transformative antisense oligonucleotides have landed. Many are delivered as one-off or small-course treatments at specialist centres, with long-tail aftercare filtering back to community pharmacy in the form of antiviral, antibiotic and supportive medicines.

How the pathway actually works

The process for a new ultra-rare medicine is broadly:

1. Scoping. NICE confirms whether the medicine fits the HST criteria.
2. Evidence submission. The manufacturer submits a clinical and economic dossier.
3. Committee evaluation. An HST evaluation committee reviews the submission, typically over six to twelve months, with patient and clinician input.
4. Draft guidance. A Final Evaluation Document is circulated and consulted on.
5. Final guidance. NICE publishes the final guidance; NHS England then commissions the service.
6. Managed access where required. If long-term data is uncertain, a Managed Access Agreement is put in place.

The practical upshot is that between a medicine receiving MHRA marketing authorisation and being routinely available to NHS patients, there is often a one- to two-year window during which access runs through trial, named-patient or EAMS-style routes. HST guidance is what converts the medicine from "approved to be sold" to "funded to be used".

Why this matters for pharmacy

Community and hospital pharmacy sit on opposite ends of the HST-approved medicine journey.

Hospital pharmacy manages the primary dispensing and administration of HST-approved advanced therapies. This requires specialist cold-chain, aseptic and records infrastructure, plus close coordination with clinical nurse specialists and specialist commissioners. A hospital pharmacist in a tertiary haematology centre today may be handling Casgevy preparations that did not exist as NHS-reimbursed products two years ago.

Community pharmacy handles the long-tail aftercare. Patients who have received an HST-approved therapy continue to collect aciclovir, co-trimoxazole, levothyroxine, antifungals and routine chronic medication from their local high-street pharmacy. They may carry an alert card (see our specialist-therapy aftercare piece) identifying the treatment and the treating centre.

Primary care pharmacy in Primary Care Networks increasingly features clinical pharmacists supporting rare-disease patients between specialist reviews. These are the pharmacists who may pick up gaps in monitoring, interactions with newly prescribed primary-care medicines, and signposting to specialist contacts.

Where HST decisions are unlikely to reach

Not every rare-disease medicine is routed through HST. Those that affect slightly larger populations, or that are expected to be used alongside existing therapies rather than replacing them, may go through standard Technology Appraisal instead. The UK Rare Diseases Action Plan 2026 sets out ambitions to streamline the boundary between the two routes and to reduce the time between MHRA licensing and NHS availability.

For now, the practical reality is that a UK patient with an ultra-rare diagnosis may spend months waiting for HST guidance even after their medicine has been approved elsewhere in the world. The role of pharmacy is to keep the supportive care robust through that waiting period and to be informed once the guidance is published.

Further reading on PharmSee

• Pharmacy workforce dashboard: /salary
• Live pharmacy vacancies including PCN rare-disease roles: /app/jobs
• Pharmacy locator: /app/pharmacies

Caveats

This piece summarises the NICE HST pathway as it operated up to April 2026. The list of HST-approved medicines changes regularly; NICE's own register is the authoritative source. Specific clinical, eligibility and commissioning arrangements for any named therapy should be checked with the treating specialist centre and the NHS England specialised commissioning page.

Sources

• NICE, Highly Specialised Technologies programme documentation and the HST register.
• NHS England, Specialised Services commissioning framework.
• Department of Health and Social Care, UK Rare Diseases Action Plan 2026.